{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:34:02Z","timestamp":1791182042205,"version":"4.1.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2015,6,9]],"date-time":"2015-06-09T00:00:00Z","timestamp":1433808000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,6,9]],"date-time":"2015-06-09T00:00:00Z","timestamp":1433808000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1038\/leu.2015.138","type":"journal-article","created":{"date-parts":[[2015,6,9]],"date-time":"2015-06-09T06:42:35Z","timestamp":1433832155000},"page":"2230-2237","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Identification of bromodomain-containing protein-4 as a novel marker and epigenetic target in mast cell leukemia"],"prefix":"10.1038","volume":"29","author":[{"given":"G","family":"Wedeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Cerny-Reiterer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Eisenwort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Blatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Hadzijusufovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Sadovnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"M\u00fcllauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Schwaab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J E","family":"Bradner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Radia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W R","family":"Sperr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Hoermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Reiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H-P","family":"Horny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Zuber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Arock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Valent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,6,9]]},"reference":[{"key":"BFleu2015138_CR1","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/S0145-2126(01)00021-2","volume":"25","author":"HP Horny","year":"2001","unstructured":"Horny HP, Valent P . Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings. Leuk Res 2001; 25: 543\u2013551.","journal-title":"Leuk Res"},{"key":"BFleu2015138_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jaci.2004.02.045","volume":"114","author":"P Valent","year":"2004","unstructured":"Valent P, Sperr WR, Schwartz LB, Horny HP . Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and non-mast cell hematopoietic neoplasms. J Allergy Clin Immunol 2004; 114: 3\u201311.","journal-title":"J Allergy Clin Immunol"},{"key":"BFleu2015138_CR3","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1159\/000101711","volume":"74","author":"HP Horny","year":"2007","unstructured":"Horny HP, Sotlar K, Valent P . Mastocytosis: state of the art. Pathobiology 2007; 74: 121\u2013132.","journal-title":"Pathobiology"},{"key":"BFleu2015138_CR4","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1182\/blood-2007-11-078097","volume":"112","author":"DD Metcalfe","year":"2008","unstructured":"Metcalfe DD . Mast cells and mastocytosis. Blood 2008; 112: 946\u2013956.","journal-title":"Blood"},{"key":"BFleu2015138_CR5","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1586\/ehm.10.42","volume":"3","author":"M Arock","year":"2010","unstructured":"Arock M, Valent P . Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives. Expert Rev Hematol 2010; 3: 497\u2013516.","journal-title":"Expert Rev Hematol"},{"key":"BFleu2015138_CR6","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/S0145-2126(01)00038-8","volume":"25","author":"P Valent","year":"2001","unstructured":"Valent P, Horny HP, Escribano L, Longley BJ, Li CY, Schwartz LB et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 2001; 25: 603\u2013625.","journal-title":"Leuk Res"},{"key":"BFleu2015138_CR7","first-page":"291","volume-title":"WHO Classification of Tumours","author":"P Valent","year":"2001","unstructured":"Valent P, Horny HP, Li CY, Longley JB, Metcalfe DD, Parwaresch RM et al. Mastocytosis. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds). WHO Classification of Tumours. IARC Press: Lyon, France, 2001, pp 291\u2013302."},{"key":"BFleu2015138_CR8","first-page":"54","volume-title":"WHO Classification of Tumours","author":"HP Horny","year":"2008","unstructured":"Horny HP, Akin C, Metcalfe D, Escribano L, Bennett JM, Valent P et al. Mastocytosis (mast cell disease) Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al. WHO Classification of Tumours. IARC Press: Lyon, France, 2008, 54\u201363."},{"key":"BFleu2015138_CR9","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1111\/j.1365-2362.2007.01807.x","volume":"37","author":"P Valent","year":"2007","unstructured":"Valent P, Akin C, Escribano L, F\u00f6dinger M, Hartmann K, Brockow K et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 2007; 37: 435\u2013453.","journal-title":"Eur J Clin Invest"},{"key":"BFleu2015138_CR10","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0025-6196(12)62636-6","volume":"61","author":"WD Travis","year":"1986","unstructured":"Travis WD, Li CY, Hoagland HC, Travis LB, Banks PM . Mast cell leukemia: report of a case and review of the literature. Mayo Clin Proc 1986; 61: 957\u2013966.","journal-title":"Mayo Clin Proc"},{"key":"BFleu2015138_CR11","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/S0145-2126(01)00041-8","volume":"25","author":"WR Sperr","year":"2001","unstructured":"Sperr WR, Escribano L, Jordan JH, Schernthaner GH, Kundi M, Horny HP et al. Morphologic properties of neoplastic mast cells: delineation of stages of maturation and implication for cytological grading of mastocytosis. Leuk Res 2001; 25: 529\u2013536.","journal-title":"Leuk Res"},{"key":"BFleu2015138_CR12","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/S0145-2126(02)00168-6","volume":"27","author":"P Valent","year":"2003","unstructured":"Valent P, Akin C, Sperr WR, Escribano L, Arock M, Horny HP et al. Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. Leuk Res 2003; 27: 635\u2013641.","journal-title":"Leuk Res"},{"key":"BFleu2015138_CR13","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1146\/annurev.med.55.091902.103822","volume":"55","author":"C Akin","year":"2004","unstructured":"Akin C, Metcalfe DD . Systemic mastocytosis. Annu Rev Med 2004; 55: 419\u2013432.","journal-title":"Annu Rev Med"},{"key":"BFleu2015138_CR14","doi-asserted-by":"publisher","first-page":"5727","DOI":"10.1182\/blood-2009-02-205237","volume":"113","author":"KH Lim","year":"2009","unstructured":"Lim KH, Tefferi A, Lasho TL, Finke C, Patnaik M, Butterfield JH et al. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood 2009; 113: 5727\u20135736.","journal-title":"Blood"},{"key":"BFleu2015138_CR15","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/j.0960-135X.2004.01369.x","volume":"34","author":"P Valent","year":"2004","unstructured":"Valent P, Ghannadan M, Akin C, Krauth MT, Selzer E, Mayerhofer M et al. On the way to targeted therapy of mast cell neoplasms: identification of molecular targets in neoplastic mast cells and evaluation of arising treatment concepts. Eur J Clin Invest 2004; 34: 41\u201352.","journal-title":"Eur J Clin Invest"},{"key":"BFleu2015138_CR16","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1182\/blood-2012-07-442400","volume":"121","author":"S Georgin-Lavialle","year":"2013","unstructured":"Georgin-Lavialle S, Lhermitte L, Dubreuil P, Chandesris MO, Hermine O, Damaj G . Mast cell leukemia. Blood 2013; 121: 1285\u20131295.","journal-title":"Blood"},{"key":"BFleu2015138_CR17","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.iac.2006.05.003","volume":"26","author":"J Gotlib","year":"2006","unstructured":"Gotlib J . KIT mutations in mastocytosis and their potential as therapeutic targets. Immunol Allergy Clin North Am 2006; 26: 575\u2013592.","journal-title":"Immunol Allergy Clin North Am"},{"key":"BFleu2015138_CR18","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/j.leukres.2011.05.006","volume":"35","author":"C Ustun","year":"2011","unstructured":"Ustun C, DeRemer DL, Akin C . Tyrosine kinase inhibitors in the treatment of systemic mastocytosis. Leuk Res 2011; 35: 1143\u20131152.","journal-title":"Leuk Res"},{"key":"BFleu2015138_CR19","doi-asserted-by":"publisher","first-page":"10560","DOI":"10.1073\/pnas.92.23.10560","volume":"92","author":"H Nagata","year":"1995","unstructured":"Nagata H, Worobec AS, Oh CK, Chowdhury BA, Tannenbaum S, Suzuki Y et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci USA 1995; 92: 10560\u201310564.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu2015138_CR20","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/ng0396-312","volume":"12","author":"BJ Longley","year":"1996","unstructured":"Longley BJ, Tyrrell L, Lu SZ, Ma YS, Langley K, Ding TG et al. Somatic c-kit activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat Genet 1996; 12: 312\u2013314.","journal-title":"Nat Genet"},{"key":"BFleu2015138_CR21","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1046\/j.1365-2141.2001.02783.x","volume":"113","author":"R Fritsche-Polanz","year":"2001","unstructured":"Fritsche-Polanz R, Jordan JH, Feix A, Sperr WR, Sunder-Plassmann G, Valent P et al. Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis. Br J Haematol 2001; 113: 357\u2013364.","journal-title":"Br J Haematol"},{"key":"BFleu2015138_CR22","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1172\/JCI116761","volume":"92","author":"T Furitsu","year":"1993","unstructured":"Furitsu T, Tsujimura T, Tono T, Kitayama H, Koshimizu U, Sugahara H et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of the c-kit product. J Clin Invest 1993; 92: 1736\u20131744.","journal-title":"J Clin Invest"},{"key":"BFleu2015138_CR23","doi-asserted-by":"publisher","first-page":"5466","DOI":"10.4049\/jimmunol.180.8.5466","volume":"180","author":"M Mayerhofer","year":"2008","unstructured":"Mayerhofer M, Gleixner KV, Hoelbl A, Florian S, Hoermann G, Aichberger KJ et al. Unique effects of KIT D816V in BaF3 cells: induction of cluster formation, histamine synthesis, and early mast cell differentiation antigens. J Immunol 2008; 180: 5466\u20135476.","journal-title":"J Immunol"},{"key":"BFleu2015138_CR24","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1182\/blood-2005-07-3022","volume":"107","author":"KV Gleixner","year":"2006","unstructured":"Gleixner KV, Mayerhofer M, Aichberger KJ, Derdak S, Sonneck K, B\u00f6hm A et al. The tyrosine kinase-targeting drug PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of kit: comparison with AMN107, imatinib, and cladribine (2CdA), and evaluation of cooperative drug effects. Blood 2006; 107: 752\u2013759.","journal-title":"Blood"},{"key":"BFleu2015138_CR25","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1182\/blood-2005-10-3969","volume":"108","author":"NP Shah","year":"2006","unstructured":"Shah NP, Lee FY, Luo R, Jiang Y, Donker M, Akin C . Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood 2006; 108: 286\u2013291.","journal-title":"Blood"},{"key":"BFleu2015138_CR26","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.3324\/haematol.11339","volume":"92","author":"KV Gleixner","year":"2007","unstructured":"Gleixner KV, Mayerhofer M, Sonneck K, Gruze A, Samorapoompichit P, Baumgartner C et al. Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT. Haematologica 2007; 92: 1451\u20131459.","journal-title":"Haematologica"},{"key":"BFleu2015138_CR27","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1182\/blood-2005-04-1568","volume":"106","author":"J Gotlib","year":"2005","unstructured":"Gotlib J, Berube C, Growney JD, Chen CC, George TI, Williams C et al. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood 2005; 106: 2865\u20132870.","journal-title":"Blood"},{"key":"BFleu2015138_CR28","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1182\/blood.V116.21.316.316","volume":"116","author":"J Gotlib","year":"2010","unstructured":"Gotlib J, DeAngelo DJ, George TI, Corless CL, Linder A, Langford C et al. KIT inhibitor midostaurin exhibits a high rate of clinically meaningful and durable responses in advanced systemic mastocytosis: report of fully accrued phase II trial. Blood 2010; 116: 316.","journal-title":"Blood"},{"key":"BFleu2015138_CR29","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1056\/NEJMra1112635","volume":"367","author":"MA Dawson","year":"2012","unstructured":"Dawson MA, Kouzarides T, Huntly BJ . Targeting epigenetic readers in cancer. N Engl J Med 2012; 367: 647\u2013657.","journal-title":"N Engl J Med"},{"key":"BFleu2015138_CR30","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1056\/NEJMcibr1113401","volume":"366","author":"LA Godley","year":"2012","unstructured":"Godley LA, Le Beau MM . The histone code and treatments for acute myeloid leukemia. N Engl J Med 2012; 366: 960\u2013961.","journal-title":"N Engl J Med"},{"key":"BFleu2015138_CR31","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/nrc3256","volume":"12","author":"AC Belkina","year":"2012","unstructured":"Belkina AC, Denis GV . BET domain co-regulators in obesity, inflammation and cancer. Nat Rev Cancer 2012; 12: 465\u2013477.","journal-title":"Nat Rev Cancer"},{"key":"BFleu2015138_CR32","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/nature10334","volume":"478","author":"J Zuber","year":"2011","unstructured":"Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 2011; 478: 524\u2013528.","journal-title":"Nature"},{"key":"BFleu2015138_CR33","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.18632\/oncotarget.733","volume":"3","author":"H Herrmann","year":"2012","unstructured":"Herrmann H, Blatt K, Shi J, Gleixner KV, Cerny-Reiterer S, M\u00fcllauer L et al. Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia AML. Oncotarget 2012; 3: 1588\u20131599.","journal-title":"Oncotarget"},{"key":"BFleu2015138_CR34","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/S0002-9440(10)63870-9","volume":"162","author":"K Sotlar","year":"2003","unstructured":"Sotlar K, Escribano L, Landt O, M\u00f6hrle S, Herrero S, Torrelo A et al. One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes. Am J Pathol 2003; 162: 737\u2013746.","journal-title":"Am J Pathol"},{"key":"BFleu2015138_CR35","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/0145-2126(88)90050-1","volume":"12","author":"JH Butterfield","year":"1988","unstructured":"Butterfield JH, Weiler D, Dewald G, Gleich GJ . Establishment of an immature mast cell line from a patient with mast cell leukemia. Leuk Res 1988; 12: 345\u2013355.","journal-title":"Leuk Res"},{"key":"BFleu2015138_CR36","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/S0301-472X(03)00112-7","volume":"31","author":"C Akin","year":"2003","unstructured":"Akin C, Brockow K, D'Ambrosio C, Kirshenbaum AS, Ma Y, Longley BJ et al. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Exp Hematol 2003; 31: 686\u2013692.","journal-title":"Exp Hematol"},{"key":"BFleu2015138_CR37","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1182\/blood-2013-10-534685","volume":"124","author":"R Saleh","year":"2014","unstructured":"Saleh R, Wedeh G, Herrmann H, Bibi S, Cerny-Reiterer S, Sadovnik I et al. A new human mast cell line expressing a functional IgE receptor converts to factor-independence and tumorigenicity by KIT D816V-transfection. Blood 2014; 124: 111\u2013120.","journal-title":"Blood"},{"key":"BFleu2015138_CR38","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1016\/j.celrep.2013.11.020","volume":"5","author":"C Fellmann","year":"2013","unstructured":"Fellmann C, Hoffmann T, Sridhar V, Hopfgartner B, Muhar M, Roth M et al. An optimized microRNA backbone for effective single-copy RNAi. Cell Rep 2013; 5: 1704\u20131713.","journal-title":"Cell Rep"},{"key":"BFleu2015138_CR39","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.2353\/ajpath.2009.080953","volume":"175","author":"C Baumgartner","year":"2009","unstructured":"Baumgartner C, Cerny-Reiterer S, Sonneck K, Mayerhofer M, Gleixner KV, Fritz R et al. Expression of activated STAT5 in neoplastic mast cells in systemic mastocytosis: subcellular distribution and role of the transforming oncoprotein KIT D816V. Am J Pathol 2009; 175: 2416\u20132429.","journal-title":"Am J Pathol"},{"key":"BFleu2015138_CR40","doi-asserted-by":"publisher","first-page":"672","DOI":"10.3324\/haematol.2010.031328","volume":"96","author":"B Peter","year":"2011","unstructured":"Peter B, Gleixner KV, Cerny-Reiterer S, Herrmann H, Winter V, Hadzijusufovic E et al. Polo-like kinase-1 as a novel target in neoplastic mast cells: demonstration of growth-inhibitory effects of small interfering RNA and the Polo-like kinase-1 targeting drug BI 2536. Haematologica 2011; 96: 672\u2013680.","journal-title":"Haematologica"},{"key":"BFleu2015138_CR41","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1182\/blood-2007-08-104372","volume":"111","author":"M Kneidinger","year":"2008","unstructured":"Kneidinger M, Schmidt U, Rix U, Gleixner KV, Vales A, Baumgartner C et al. The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils. Blood 2008; 111: 3097\u20133107.","journal-title":"Blood"},{"key":"BFleu2015138_CR42","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1111\/j.1365-2222.2009.03353.x","volume":"39","author":"MT Krauth","year":"2009","unstructured":"Krauth MT, Mirkina I, Herrmann H, Baumgartner C, Kneidinger M, Valent P . Midostaurin (PKC412) inhibits immunoglobulin E-dependent activation and mediator release in human blood basophils and mast cells. Clin Exp Allergy 2009; 39: 1711\u20131720.","journal-title":"Clin Exp Allergy"},{"key":"BFleu2015138_CR43","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1158\/1535-7163.MCT-13-0770","volume":"13","author":"W Fiskus","year":"2014","unstructured":"Fiskus W, Sharma S, Qi J, Valenta JA, Schaub LJ, Shah B et al. Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myeloid leukemia (AML) cells. Mol Cancer Ther 2014; 13: 1142\u20131154.","journal-title":"Mol Cancer Ther"},{"key":"BFleu2015138_CR44","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1182\/blood-2013-08-522698","volume":"123","author":"JE Roderick","year":"2014","unstructured":"Roderick JE, Tesell J, Shultz LD, Brehm MA, Greiner DL, Harris MH et al. c-Myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T-ALL cells. Blood 2014; 123: 1040\u20131050.","journal-title":"Blood"},{"key":"BFleu2015138_CR45","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1182\/blood-2012-02-413021","volume":"120","author":"CJ Ott","year":"2012","unstructured":"Ott CJ, Kopp N, Bird L, Paranal RM, Qi J, Bowman T et al. BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood 2012; 120: 2843\u20132852.","journal-title":"Blood"},{"key":"BFleu2015138_CR46","doi-asserted-by":"publisher","first-page":"9059","DOI":"10.1128\/MCB.24.20.9059-9069.2004","volume":"24","author":"A Farina","year":"2004","unstructured":"Farina A, Hattori M, Qin J, Nakatani Y, Minato N, Ozato K . Bromodomain protein Brd4 binds to GTPase-activating SPA-1, modulating its activity and subcellular localization. Mol Cell Biol 2004; 24: 9059\u20139069.","journal-title":"Mol Cell Biol"},{"key":"BFleu2015138_CR47","doi-asserted-by":"publisher","first-page":"6927","DOI":"10.1073\/pnas.1120422109","volume":"109","author":"BN Devaiah","year":"2012","unstructured":"Devaiah BN, Lewis BA, Cherman N, Hewitt MC, Albrecht BK, Robey PG et al. BRD4 is an atypical kinase that phosphorylates serine2 of the RNA polymerase II carboxy-terminal domain. Proc Natl Acad Sci USA 2012; 109: 6927\u20136932.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu2015138_CR48","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1182\/blood-2010-06-289959","volume":"118","author":"KV Gleixner","year":"2011","unstructured":"Gleixner KV, Mayerhofer M, Cerny-Reiterer S, H\u00f6rmann G, Rix U, Bennett KL et al. KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib. Blood 2011; 118: 1885\u20131898.","journal-title":"Blood"},{"key":"BFleu2015138_CR49","doi-asserted-by":"publisher","first-page":"459","DOI":"10.3324\/haematol.2010.031690","volume":"96","author":"TM Wilson","year":"2011","unstructured":"Wilson TM, Maric I, Simakova O, Bai Y, Chan EC, Olivares N et al. Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis. Haematologica 2011; 96: 459\u2013463.","journal-title":"Haematologica"},{"key":"BFleu2015138_CR50","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1182\/blood-2013-04-496448","volume":"122","author":"J Schwaab","year":"2013","unstructured":"Schwaab J, Schnittger S, Sotlar K, Walz C, Fabarius A, Pfirrmann M et al. Comprehensive mutational profiling in advanced systemic mastocytosis. Blood 2013; 122: 2460\u20132466.","journal-title":"Blood"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2015138.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2015138","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2015138.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T16:28:23Z","timestamp":1648744103000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2015138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,9]]},"references-count":50,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["BFleu2015138"],"URL":"https:\/\/doi.org\/10.1038\/leu.2015.138","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,9]]},"assertion":[{"value":"21 December 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JEB is a scientific founder of Tensha Therapeutics, which is developing drug-like derivatives of the JQ1 bromodomain inhibitor as cancer therapeutics, through a license from the Dana-Farber Cancer Institute. H-PH has a consultancy with and received honoraria from Novartis. PV has a consultancy with and received honoraria and research funding from Novartis. The authors declare no other conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}